Drug intelligence / Profile preview

c610

Development stage: Phase 2
Lead developer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

C610 is an investigational cell therapy classified as a T-lymphocyte cell therapy, developed for the treatment of advanced malignant solid neoplasms. The drug is designed to leverage immunologic cytotoxicity and T lymphocyte replacement mechanisms, aiming to enhance the immune system's ability to target and destroy cancer cells. It is being developed by Cancer Hospital Chinese Academy of Medical Sciences and has reached Phase 1/2 clinical trials for advanced solid tumors[1][4][5].

Beyond the preview

Go deeper on c610.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on c610.

Explore the full profile